Link to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-17 03:23:262021-01-05 03:26:20ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR IN ACCORDANCE WITH THE TERMS OF FORMULATION DEVELOPMENT AGREEMENT
Link to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-16 02:38:062020-12-17 02:44:27ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE
Link to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-14 02:33:002020-12-17 02:37:46ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES
Link to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected by the Armata shareholders […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-09 02:44:522020-12-17 02:46:09Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
Melbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-09 00:36:412020-12-10 00:37:58BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award
Link to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]
Melbourne, Australia 7 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd has received the 2020 Best Venture Capital Investment Award at the prestigious Australian Investment Council Investing for Growth Awards 2020. The Best Venture Capital Investment Award recognises BioScience Managers’ patient eight-year investment in AVITA Therapeutics, Inc., a regenerative medicine company that […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-07 01:33:442020-12-07 01:36:26AVITA Therapeutics Powers BioScience Managers to Prestigious Australian Investment Council Award
Link to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of General Meeting and Total Voting Rights Brighton, United Kingdom ‐ 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-11-26 03:20:002020-12-07 03:25:30Destiny Pharma – Result of General Meeting and Total Voting Rights
Link to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of Open Offer Brighton, United Kingdom ‐ 25 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that it has conditionally raised total gross proceeds of approximately £0.87m […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-11-25 03:14:172020-12-07 03:19:24Destiny Pharma announces total gross proceeds raised via Open Offer
Link to Full Article Melbourne, Australia – 24 November 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, is pleased to announce agreement of terms with leading respiratory company Monaghan Medical Corporation (Monaghan) to support the introduction of its Hailie® platform and technology into specialist respiratory centres in […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-11-24 02:55:582020-12-07 02:57:35Adherium introduces Hailie® technology into specialist USA respiratory centres with leading USA respiratory company
ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR IN ACCORDANCE WITH THE TERMS OF FORMULATION DEVELOPMENT AGREEMENT
/in ArecorLink to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE
/in ArecorLink to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]
ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES
/in ArecorLink to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
/in Armata PharmaceuticalsLink to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected by the Armata shareholders […]
BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award
/in BioSciences ManagersMelbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]
GEN INCODE APPOINTS CHIEF FINANCIAL OFFICER
/in GenInCodeLink to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]
AVITA Therapeutics Powers BioScience Managers to Prestigious Australian Investment Council Award
/in Avita MedicalMelbourne, Australia 7 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd has received the 2020 Best Venture Capital Investment Award at the prestigious Australian Investment Council Investing for Growth Awards 2020. The Best Venture Capital Investment Award recognises BioScience Managers’ patient eight-year investment in AVITA Therapeutics, Inc., a regenerative medicine company that […]
Destiny Pharma – Result of General Meeting and Total Voting Rights
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of General Meeting and Total Voting Rights Brighton, United Kingdom ‐ 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier […]
Destiny Pharma announces total gross proceeds raised via Open Offer
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of Open Offer Brighton, United Kingdom ‐ 25 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that it has conditionally raised total gross proceeds of approximately £0.87m […]
Adherium introduces Hailie® technology into specialist USA respiratory centres with leading USA respiratory company
/in AdheriumLink to Full Article Melbourne, Australia – 24 November 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, is pleased to announce agreement of terms with leading respiratory company Monaghan Medical Corporation (Monaghan) to support the introduction of its Hailie® platform and technology into specialist respiratory centres in […]